News

“We are excited to complete our first regulatory submission for CABOMETYX in combination with an immune-checkpoint inhibitor based on the positive results from the CheckMate -9ER phase 3

Forbius is engaged in the designing and development of advanced biotherapeutics to treat cancer and fibrotic diseases. The company has developed a portfolio of selective and potent inhibitors

The trial was conducted among untreated patients with unresectable (Stage IIIC) or metastatic (Stage IV) BRAF V600 mutation-positive cutaneous melanoma, compared to Tafinlar + Mekinist alone. “While the

The US-based clinical-stage biopharmaceutical company had recently launched a phase 1 trial for SAB-185 in healthy volunteers to evaluate its safety. Apart from its potential treatment of Covid-19,

Today’s action follows the FDA’s extensive review of the science and data generated over the past several months stemming from efforts to facilitate emergency access to convalescent plasma

Oscar A-Co KK, a company controlled by funds managed by The Blackstone Group and its affiliates, has signed an agreement to acquire Takeda’s wholly-owned subsidiary Takeda Consumer Healthcare

OrthoMab is a clinically validated platform that uses the most advanced computational and experimental protein engineering methods to create IgG-like bispecific antibodies from any two antibody sequences. By

The newly released manuscript describes key safety and immunogenicity data from the U.S. Phase 1 trial for the BNT162b2 vaccine candidate, which at 30μg recorded 7 days after

The approval allows Kesimpta to be used as an injection for subcutaneous use to treat RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in